Randomised study of rituximab (IDEC C2B8) in patients with relapsed follicular lymphoma prior to high dose therapy as in vivo purging and to maintain remission following high dose therapy

Trial Profile

Randomised study of rituximab (IDEC C2B8) in patients with relapsed follicular lymphoma prior to high dose therapy as in vivo purging and to maintain remission following high dose therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2005

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top